Completed OBSERVATIONAL NCT04874740

Seroprevalence of the Anti-SARS-CoV-2 Antibodies (Causing COVID-19) in Kidney Transplant Recipients in Severely Affected Region (SECOVtx)

Seroprevalence of the Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients in Severely Affected Region

Sponsor: University Hospital Ostrava

Conditions COVID-19 Pandemic Transplantation, Kidney

Updated 4 times since 2021 Last updated: Dec 6, 2022 Started: Apr 30, 2021 Primary completion: Oct 30, 2022 Completion: Oct 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on COVID-19 Pandemic and Transplantation, Kidney, this trial is completed. The trial is conducted by University Hospital Ostrava and has accumulated 4 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2023 — Jul 2024 [monthly]

Completed

Status: Recruiting → Completed
Jun 2021 — Jan 2023 [monthly]

Recruiting

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University Hospital Ostrava

Data source: University Hospital Ostrava

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ostrava, Czechia